FDA Approves 35 Novel Medicines in Fiscal Year 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Approves 35 Novel Medicines in Fiscal Year 2011

ePT--the Electronic Newsletter of Pharmaceutical Technology

At a press conference held Nov. 10, 2011, FDA Commissioner Margaret Hamburg said the agency had approved 35 novel medicines in fiscal year 2011. Among the approved products were two drugs for late-stage metastatic melanoma and the first drug to treat Hodgkins lymphoma in 30 years. Other approvals included drugs to treat late-stage prostate cancer, thyroid cancer, metastatic breast cancer, and late-stage lung cancer.

Hamburg highlighted the agency’s efforts to bring new drugs to market quickly and efficiently while maintaining high standards for drug safety and effectiveness. “FDA approved nearly 70% of these 35 new drugs before any other regulatory agency in the world,” she said. Of the 23 cancer drugs approved between 2003 and 2010 by FDA and the European Medicines Agency, all 23 were approved first in the US, said Hamburg, citing a study published in Health Affairs.

FDA has expanded its drug-approval pathways to include Fast Track, Accelerated Approval, Priority Review, and Expanded Access programs, which are designed to speed the testing, availability, and approval of drugs in various ways. Almost half of the 35 new drugs approved in fiscal year 2011 were approved under priority review, said Hamburg. Under this program, FDA aims to complete its review of safety and effectiveness in six months.

The agency also has shown flexibility regarding clinical trials. Clinical requirements for many of the newly approved drugs were streamlined to permit smaller, shorter, or fewer studies than previous studies. FDA approved several drugs on the basis of single-arm studies or studies with extremely small patient populations, Hamburg said.

FDA’s efforts to modernize its regulatory pathways depend on its initiatives to strengthen regulatory science, said Hamburg. The agency’s Advancing Regulatory Science Initiative currently seeks to identify opportunities to invest in regulatory science. Last year, FDA and the National Institutes of Health launched a Regulatory Science Initiative to encourage research in this field. The agency also established several Centers of Excellence in Regulatory Science, including sites at Georgetown University and at the University of Maryland.

See related Pharm Tech articles:

Accelerated Approvals Could Raise Risks for Patients (blog post)

FDA Establishes Two Centers for Regulatory Science (ePT)

FDA Outlines Strategy to Spur Biomedical Innovation (ePT)


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here